Literature DB >> 31542260

Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Young-Man Kwon1, Youri Lee1, Ki Hye Kim1, Yu Jin Jung1, Zhuo Li1, Subbiah Jeeva1, Sujin Lee2, Martin L Moore3, Sang-Moo Kang4.   

Abstract

Pre-fusion stabilizing mutations (DS-Cav1) in soluble fusion (F) proteins of human respiratory syncytial virus (RSV) were previously reported. Here we investigated the antigenic and immunogenic properties of pre-fusion like RSV F proteins on enveloped virus-like particles (VLP). Additional mutations were introduced to DS-Cav1 (F-dcmTM VLP); fusion peptide deletion and cleavage mutation site 1 (F1d-dcmTM VLP) or both sites (F12d-dcmTM VLP). F1d-dcmTM VLP and F12d-dcmTM VLP displayed higher reactivity against pre-fusion specific site Ø and antigenic site I and II specific monoclonal antibodies, compared to F-dcmTM VLP with DS-Cav1 only. Mice immunized with F1d-dcmTM VLP and F12d-dcmTM VLP induced higher levels of DS-Cav1 pre-fusion specific IgG antibodies, RSV neutralizing activity titers, and effective lung viral clearance after challenge. These results suggest that cleavage site mutations and fusion peptide deletion in addition to DS-Cav1 mutations have contributed to structural stabilization of pre-fusion like F conformation on enveloped VLP, capable of inducing high levels of pre-fusion F specific and RSV neutralizing antibodies.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  P27; Post-fusion transition; Prefusion; RSV; RSV F protein; VLP

Year:  2019        PMID: 31542260      PMCID: PMC6893914          DOI: 10.1016/j.vaccine.2019.09.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

Review 1.  Palivizumab in the prophylaxis of respiratory syncytial virus infection.

Authors:  Silvia Cardenas; Alexander Auais; Giovanni Piedimonte
Journal:  Expert Rev Anti Infect Ther       Date:  2005-10       Impact factor: 5.091

2.  Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.

Authors:  Jason S McLellan; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

3.  Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Min-Chul Kim; Eun-Ju Ko; Jong Seok Lee; Youri Lee; Sang-Moo Kang
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

Review 4.  Vaccine development for respiratory syncytial virus.

Authors:  Barney S Graham
Journal:  Curr Opin Virol       Date:  2017-05-16       Impact factor: 7.090

5.  Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein.

Authors:  Brett D Welch; Yuanyuan Liu; Christopher A Kors; George P Leser; Theodore S Jardetzky; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

6.  Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.

Authors:  Shannon I Phan; James R Zengel; Huiling Wei; Zhuo Li; Dai Wang; Biao He
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

7.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

8.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Authors:  Youri Lee; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Soojin Park; Young-Man Kwon; Sang Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

9.  The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Authors:  Kate L Stokes; Michael G Currier; Kaori Sakamoto; Sujin Lee; Peter L Collins; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

10.  A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard.

Authors:  Nancy Hosken; Brian Plikaytis; Carrie Trujillo; Kutub Mahmood; Deborah Higgins
Journal:  Vaccine       Date:  2017-05-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.